argenx (NASDAQ:ARGX) Upgraded at William Blair

William Blair upgraded shares of argenx (NASDAQ:ARGX) from a market perform rating to an outperform rating in a research report report published on Friday, Marketbeat Ratings reports. William Blair also issued estimates for argenx’s Q4 2024 earnings at $0.35 EPS.

A number of other research firms also recently commented on ARGX. Citigroup increased their target price on argenx from $512.00 to $635.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Evercore ISI lifted their price objective on shares of argenx from $478.00 to $533.00 and gave the stock an “outperform” rating in a research note on Friday, July 12th. Oppenheimer upgraded shares of argenx from a “market perform” rating to an “outperform” rating and set a $546.00 target price on the stock in a research report on Tuesday, July 23rd. Wedbush lifted their price target on argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Finally, Truist Financial boosted their price objective on argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a research note on Thursday. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and a consensus price target of $596.78.

argenx Trading Up 1.6 %

Shares of ARGX stock opened at $595.58 on Friday. The company’s fifty day simple moving average is $539.46 and its two-hundred day simple moving average is $466.48. argenx has a 52 week low of $327.73 and a 52 week high of $610.73.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative return on equity of 0.96% and a negative net margin of 2.11%. During the same period in the previous year, the business earned ($1.25) earnings per share. On average, sell-side analysts forecast that argenx will post -0.36 EPS for the current fiscal year.

Institutional Trading of argenx

Several institutional investors and hedge funds have recently modified their holdings of ARGX. J.Safra Asset Management Corp lifted its position in argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after acquiring an additional 59 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after purchasing an additional 62 shares during the last quarter. GAMMA Investing LLC grew its stake in argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares during the last quarter. Cromwell Holdings LLC increased its position in argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after buying an additional 66 shares in the last quarter. Finally, Point72 Hong Kong Ltd purchased a new stake in argenx in the second quarter valued at about $76,000. Institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.